| Company Name: |
Zhengzhou HSH Science & Technology Co., Ltd.
|
| Tel: |
0371-55932928 18937192232 |
| Email: |
1282296214@qq.com |
| Products Intro: |
Product Name:N-(4-(2-cyanopropan-2-yl)phenyl)-3-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxamide;CHIKV-IN-2 CAS:2361289-44-1 Purity:98% HPLC Package:100g;10g;5g;1g;500mg;250mg;100mg;10mg;5mg
|
5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy- manufacturers
- CHIKV-IN-2
-
- $37.00
-
2026-04-20
- CAS:2361289-44-1
- Purity: 98.67%
- Supply Ability: 10g
|
| | 5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy- Basic information |
| Product Name: | 5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy- | | Synonyms: | 5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy-;N-(4-(2-cyanopropan-2-yl)phenyl)-3-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxamide;CHIKV-IN-2;Dihydroorotate Dehydrogenase,CHIKV,DHODH,virus,inhibit,CHIKV IN 2,Chikungunya,Inhibitor,CHIKVIN2;CHIKV-IN-2, 10 mM in DMSO | | CAS: | 2361289-44-1 | | MF: | C23H26N2O2 | | MW: | 362.46 | | EINECS: | | | Product Categories: | | | Mol File: | 2361289-44-1.mol | ![5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy- Structure](CAS/20210305/GIF/2361289-44-1.gif) |
| | 5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy- Chemical Properties |
| Boiling point | 504.8±50.0 °C(Predicted) | | density | 1.143±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (275.89 mM; Need ultrasonic) | | pka | 13.28±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | 5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy- Usage And Synthesis |
| Uses | CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC90=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools[1]. | | Biological Activity | CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC90=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools[1].
CHIKV-IN-2 (compound 8q) is a potent pan-alphavirus inhibitor, with EC90s of 0.85-2.5 μM for CHIKV clinical isolates and attenuated vaccine strains[1].CHIKV-IN-2 is active against alphavirus VEEV (EC90=0.40 μM) as well as flaviviruses such as West Nile Virus (WNV, EC90=0.20 μM) and Dengue Virus Strain-2 (DENV-2, EC90=0.60 μM)[1].
CHIKV-IN-2 (compound 8q) (80 mg/kg; i.p. twice a day for 3 days) significantly decreases infectious CHIKV dissemination to other tissues of mice[1].CHIKV-IN-2 (40 mg/kg; p.o., i.p., s.c.) exhibits moderate bioavailability (F=41%, 43%, 4%), terminal elimination half-life (t1/2=9.9, 18.5, 18.6 h) and Cmax (642, 858, 90 ng/mL) in mice[1].CHIKV-IN-2 (1 mg/kg; i.v.) exhibits terminal elimination half-life (t1/2= 2.02 h) and AUC (497 hng/mL) in mice[1]. | | in vivo | CHIKV-IN-2 (compound 8q) (80 mg/kg; i.p. twice a day for 3 days) significantly decreases infectious CHIKV dissemination to other tissues of mice[1].
CHIKV-IN-2 (40 mg/kg; p.o., i.p., s.c.) exhibits moderate bioavailability (F=41%, 43%, 4%), terminal elimination half-life (t1/2=9.9, 18.5, 18.6 h) and Cmax (642, 858, 90 ng/mL) in mice[1].
CHIKV-IN-2 (1 mg/kg; i.v.) exhibits terminal elimination half-life (t1/2= 2.02 h) and AUC (497 hng/mL) in mice[1]. | Animal Model: | Female and male C57BL/6 mice[1] | | Dosage: | 80 mg/kg | | Administration: | I.p. twice a day for 3 days | | Result: | Failed to inhibit virus loads at the site of infection.
Decreased virus dissemination to other tissues. |
| Animal Model: | Male C57BL/6 mice were challenged with CHIKV in the right footpad[1] | | Dosage: | 1 mg/kg for i.v. and 40 mg/kg for p.o., i.p., s.c. (Pharmacokinetic Analysis) | | Administration: | I.v., p.o., i.p., s.c. | | Result: | I.v.: t1/2= 2.02 h; AUC=497 hng/mL.
P.o.: F=41%; t1/2=9.9 h; Cmax=642 ng/mL.
I.p.: F=43%; t1/2=18.5 h; Cmax=858 ng/mL.
S.c.: F=4%; t1/2=18.6 h; Cmax=90 ng/mL. |
| | References | [1]. Ahmed SK, et, al. Targeting Chikungunya Virus Replication by Benzoannulene Inhibitors. J Med Chem. 2021 Apr 22;64(8):4762-4786. |
| | 5H-Benzocycloheptene-2-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-6,7,8,9-tetrahydro-3-methoxy- Preparation Products And Raw materials |
|